Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1507054 | 0.85 | HRH3 (0.50) | HRH3KCNH2ALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL3857679 | 0.84 | ALDH1A1 (0.61) | HRH3KCNH2ALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL1506985 | 0.84 | HRH3 (0.49) | HRH3KCNH2ALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL1872893 | 0.84 | HRH3 (0.49) | HRH3KCNH2ALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL1507265 | 0.83 | HRH3 (0.53) | HRH3KCNH2ALDH1A1 | |
| SCHEMBL16207888 | 0.83 | HRH3 (0.48) | HRH3KCNH2ALDH1A1POLBHSD17B10 | |
| SCHEMBL27813833 | 0.82 | HRH3 (0.61) | HRH3KCNH2ALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL1507068 | 0.82 | HRH3 (0.51) | HRH3KCNH2ALDH1A1L3MBTL3L3MBTL1 | |
| SCHEMBL1507226 | 0.81 | HRH3 (0.52) | HRH3KCNH2ALDH1A1 | |
| SCHEMBL1507140 | 0.81 | HRH3 (0.52) | HRH3KCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009135842-A1 | AZETIDINES AND CYCLOBUTANES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-11-12 | — | — | WO | disclosed |